Premium
Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole
Author(s) -
Varis Tiina,
Kaukonen KirsiMaija,
Kivistö Kari T.,
Neuvonen Pertti J.
Publication year - 1998
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/s0009-9236(98)90066-2
Subject(s) - itraconazole , methylprednisolone , placebo , crossover study , pharmacokinetics , medicine , cyp3a4 , corticosteroid , pharmacology , oral administration , glucocorticoid , chemistry , anesthesia , endocrinology , metabolism , antifungal , cytochrome p450 , alternative medicine , pathology , dermatology
Background Methylprednisolone is a widely used glucocorticoid. In this study, a possible interaction of itraconazole, a potent inhibitor of CYP3A4, with orally administered methylprednisolone was examined. Methods In this double‐blind, randomized, 2‐phase crossover study, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a dose of 16 mg methylprednisolone. Plasma concentrations of methylprednisolone, cortisol, itraconazole, and hydroxyitraconazole were determined by HPLC up to 24 hours. Results Itraconazole increased the total area under the plasma methylprednisolone concentration‐time curve 3.9‐fold compared with placebo (1968 ± 470 ng · hr/mL versus 520 ± 125 ng · hr/mL [mean ± SD]; P < .001). The peak plasma concentration of methylprednisolone was increased 1.9‐fold (221 ± 49 ng/mL versus 118 ± 25 ng/mL; P < .001), and its elimination half‐life was increased 2.4‐fold (4.4 ± 0.7 hours versus 1.9 ± 0.3 hours; P < .001) by itraconazole. The mean plasma cortisol concentration during the itraconazole phase, measured 24 hours after ingestion of methylprednisolone, was only about 13% of that during the placebo phase (18 ± 23 ng/mL versus 139 ± 60 ng/mL; P < .001). Conclusions Itraconazole considerably increases plasma concentrations and effects of oral methylprednisolone, probably by inhibiting its CYP3A4‐mediated metabolism. Care should be taken if itraconazole or other potent inhibitors of CYP3A4 are used concomitantly with oral methylprednisolone, particularly during long‐term use. Clinical Pharmacology & Therapeutics (1998) 64 , 363–368; doi: